ReviewTherapeutic advances in musculoskeletal disease2020
An update on the management of antiphospholipid syndrome.
Review in Therapeutic advances in musculoskeletal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- High-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal before urgent surgery: subanalysis of the LEX-209 randomized, active-controlled trial.Research and practice in thrombosis and haemostasis · 2026Trial
- Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Management of a Left Common Carotid Artery Aneurysm by Double Branched Endovascular Arch Replacement Using Tandem Thoracic Branch Endoprosthesis Deployments.EJVES vascular forum · 2026Article
- Severe thrombocytopenia is associated with arterial thrombotic manifestations in antiphospholipid syndrome: a two-center cohort study.Frontiers in immunology · 2026Article
- Acute myocardial infarction and antiphospholipid syndrome: an updated systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Review
- Development of a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome.Advances in rheumatology (London, England) · 2025Article
- Right Ventricular Outflow Tract Mass in Antiphospholipid Syndrome.Clinical case reports · 2025Article
- Activation of the Mammalian Target of Rapamycin Pathway in Endothelial Cells in Antiphospholipid Antibody-Positive Patients with Leg Ulcers.International journal of molecular sciences · 2025Article
- Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome.Frontiers in immunology · 2025Review
- The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature.Thrombosis journal · 2024Review
- Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.Cureus · 2024Review
- Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies.Kidney international reports · 2024Review
- Interference of lupus anticoagulant causing antiprothrombin and anti-beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized ratio methods.Research and practice in thrombosis and haemostasis · 2024Article
- Article
- Catastrophic antiphospholipid syndrome after pregnancy complicated by hemolysis, elevated liver enzymes and low platelets syndrome.Obstetric medicine · 2024Article
- Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions.Journal of clinical medicine · 2024Review
- Stability of Anticoagulation Following Acenocoumarin in Stroke Patients: Role of Pharmacogenomics and Acquired Factors.Annals of Indian Academy of Neurology · 2024Article
- Systemic Lupus Erythematosus and Lupus Nephritis Presenting as Severe Constitutional Symptoms.Cureus · 2024Article
- A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation.Blood advances · 2024Article
- Advances in Management of the Stroke Etiology One-Percenters.Current neurology and neuroscience reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent venous or arterial thrombosis with or without pregnancy morbidity in the presence of persistent antiphospholipid (aPL) autoantibodies. Anticoagulation has, until now, formed the cornerstone of treatment but a significant proportion of patients continue to experience thrombosis and pregnancy morbidity despite this treatment. Thrombosis is the most common cause of mortality and accounts for two fifths of deaths. Direct oral anticoagulant drugs represent an attractive alternative to conventional vitamin K antagonist drugs but emerging evidence suggests these may not be suitable for high-risk patients with thrombotic APS. Laboratory studies and case reports of the successful use of different classes of drugs in APS is increasing our understanding of the other pathophysiological mechanisms which may contribute to the high morbidity of APS. This review summarizes current accepted anticoagulant treatment for APS and examines other potential drugs such as immunomodulating agents, statins and novel agents such as sirolimus and defibrotide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.